1. Generics Bulletin

Mylan Shareholders Say Yes To Upjohn Merger

Shareholder Meeting Had Been Delayed Due To COVID-19 Impact

 
• By Dean Rudge

Mylan and Upjohn are aiming to combine into Viatris by the end of 2020, together ticking off regulatory and financial milestones since the deal was announced in late July last year. Mylan shareholder approval remained a condition for the deal to close – with a previous vote delayed by more than two months due to the COVID-19 pandemic.

Yes or no decision
Mylan's shareholder vote came at the same time as its AGM • Source: Shutterstock

Mylan’s shareholders have voted near unanimously in favor of the company’s proposed combination with Pfizer’s Upjohn off-patent and mature brands division, with approximately 99.6% of shareholders giving the thumbs-up for the creation of the new company, Viatris.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business